Pharmacokinetic-pharmacodynamic model of urinary δ-aminolevulinic acid reduction after givosiran treatment in patients with acute hepatic porphyria. [PDF]
CPT Pharmacometrics Syst Pharmacol, 2023 Lee J, Melch M, Robbie GJ.
europepmc +1 more source
EXPLORE B: A prospective, long-term natural history study of patients with acute hepatic porphyria with chronic symptoms. [PDF]
J Inherit Metab Dis, 2022 Cassiman D +10 more
europepmc +1 more source
Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study. [PDF]
Orphanet J Rare Dis, 2022 Wang B +8 more
europepmc +1 more source
Pink urine as an inkling for a diagnostic dilemma: acute hepatic porphyria. [PDF]
BMJ Case Rep, 2021 Ibrahim S, Rao A, Shenoy RP.
europepmc +1 more source
Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy. [PDF]
Drug Des Devel Ther, 2022 Majeed CN +4 more
europepmc +1 more source
Patient Perspective on Acute Hepatic Porphyria with Sporadic Attacks: A Chronic Disease with Substantial Health-Related Quality of Life Impacts. [PDF]
Adv Ther, 2022 Wheeden K +13 more
europepmc +1 more source
Risk of primary liver cancer in acute hepatic porphyria patients: A matched cohort study of 1244 individuals. [PDF]
J Intern Med, 2022 Lissing M +8 more
europepmc +1 more source
Hyponatremia and Abdominal Pain: A Case Report of Acute Hepatic Porphyria. [PDF]
CureusRoldão M +4 more
europepmc +1 more source
Acute hepatic porphyria masquerading as familial Mediterranean fever: results of a cross-sectional porphobilinogen screening. [PDF]
Orphanet J Rare DisMusayeva G +11 more
europepmc +1 more source